Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
POSTER: MM-1485 DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Abnormalities
Suzanne Trudel, Meral Beksaç, Luděk Pour, Sosana Delimpasi, Hang Quach, Vladimir Vorobyev, Michèle Cavo, Kazuhito Suzuki, Paweł Robak, Kristin Morris, Chee Paul Lin, Ianire Garrobo-Calleja, Giulia Fulci, Elisabet E. Manasanch, Brandon E. Kremer, MariaVictoria Mateos, Meletios A Dimopoulos (2025). POSTER: MM-1485 DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Abnormalities. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)01371-0.
Article22 days agoPOSTER: MM-1486 Minimal Residual Disease Negativity in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone: Analysis From the DREAMM-8 Trial
Suzanne Trudel, Meral Beksaç, Luděk Pour, Sosana Delimpasi, Vladimir Vorobyev, Hang Quach, Kihyun Kım, Kazuhito Suzuki, María‐Victoria Mateos, Jie Ma, Yinjiao Ma, Ianire Garrobo-Calleja, Giulia Fulci, Elisabet E. Manasanch, Neal Sule, Brandon E. Kremer, Pralay Mukhopadhyay, Joanna Opalińska, Meletios A Dimopoulos (2025). POSTER: MM-1486 Minimal Residual Disease Negativity in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone: Analysis From the DREAMM-8 Trial. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)01372-2.
Article22 days agoMM-1485: DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Abnormalities
Suzanne Trudel, Meral Beksaç, Luděk Pour, Sosana Delimpasi, Hang Quach, Vladimir Vorobyev, Michèle Cavo, Kazuhito Suzuki, Paweł Robak, Kristin Morris, Chee Paul Lin, Ianire Garrobo-Calleja, Giulia Fulci, Elisabet E. Manasanch, Brandon E. Kremer, MariaVictoria Mateos, Meletios A Dimopoulos (2025). MM-1485: DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Abnormalities. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)02742-9.
Article22 days agoMM-1486: Minimal Residual Disease Negativity in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone: Analysis From the DREAMM-8 Trial
Suzanne Trudel, Meral Beksaç, Luděk Pour, Sosana Delimpasi, Vladimir Vorobyev, Hang Quach, Kihyun Kım, Kazuhito Suzuki, María‐Victoria Mateos, Jie Ma, Yinjiao Ma, Ianire Garrobo-Calleja, Giulia Fulci, Elisabet E. Manasanch, Neal Sule, Brandon E. Kremer, Pralay Mukhopadhyay, Joanna Opalińska, Meletios A Dimopoulos (2025). MM-1486: Minimal Residual Disease Negativity in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone: Analysis From the DREAMM-8 Trial. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)02743-0.
Article22 days agoThe clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Pralay Mukhopadhyay, Hesham Abdullah, Joanna Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, María‐Victoria Mateos, Meletios A Dimopoulos, Sagar Lonial (2025). The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development. , 15(1), DOI: https://doi.org/10.1038/s41408-025-01212-0.
Article22 days ago